Care.fi raises Rs 6 Cr debt funding from RevX

IMT News Desk
IMT News Desk
· 2 min read

To drive Ayushman Bharat integration

Healthcare-focused fintech startup Care.fi has successfully raised Rs 6 crore in debt funding from RevX. Care.fi will strategically deploy the capital raised to deepen its involvement in the Ayushman Bharat scheme, in line with the rapid expansion of the initiative.

The scheme is now set to cover over 550 million beneficiaries, while the network of empanelled hospitals has grown significantly, with over 29,000 hospitals onboarded as of June 2024.

The milestone funding adds momentum to Care.fi’s mission of bridging the financing gap in India’s healthcare system through smarter, tech-enabled financial solutions. With the National Health Authority aiming for more efficient claim settlements and faster reimbursements under the new structure of Ayushman Bharat, Care.fi’s backend operational expertise is well-positioned to play a critical role in enabling this transformation.

Sidak Singh, co-founder, Care.fi, shared, “Our focus has always been to ease the burden of operational and financial processes for healthcare providers. With the Ayushman Bharat scheme becoming more centralised and 60 per cent of Hospital revenue coming from Insurance schemes, our solutions can seamlessly plug into this evolving framework and help hospitals manage claims and cash flows more effectively.”

Care.fi continues to expand its footprint across India, having already disbursed over Rs 800 crore to healthcare institutions and worked with 100+ hospitals. The startup also secured an NBFC license within two years of inception, a key milestone that validates its vision of becoming India’s first healthcare-focused fin-tech institution.

Vikrant Agrawal, co-founder at Care.fi, added, “This infusion from RevX will not only allow us to scale our operations but also enable better support for hospitals onboarded under the Ayushman Bharat initiative. We see this as a powerful step toward building a resilient and inclusive healthcare financing ecosystem in India.”

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk